PROSTAGLANDINS

摘要

Novel compounds have a formula (I) (FORMULA) wherein (FORMULA) represents a bicyclo (2, 2, 1)hept-2Z-ene, bicyclo(2, 2, 1)heptane, 7-oxabicyclo(2, 2, 1)hept-2Z-ene, 7-oxabi-cyclo(2, 2, 1)heptane, bicyclo(2, 2, 2)oct-2Z-ene or bicyclo(2, 2, 2)octane substituted at the 5-position by the group R1 and at the 6-position by the group C (R2)=NR, a 6, 6-dimethyl-bicyclo(3, 1, 1)heptane substituted at the 5-position by the group R1 and at the 6-position by the group C (R2)=NR or at the 5-position by the group C(R2)=NR and at the 6-position by the group R1, a cyclohex-1-ene or cyclohexane substituted at the 4-position by the group R1 and at the 5-position by the group C(R2)=NR, or a 1-hydroxycyclopentane substituted at the 2-position by the group R1 and at the 2-position by the group C(R2)=NR, R1 is a 6-caboxyhex-2-enyl group or a modification thereof as defined herein, R2 is hydrogen, an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, and R is a group -OR3, -OR4, -A-R3 or -N=R5 in which A is -NH-, -NH.CO-, - NH.CO.CH2N(R6)-, -NH.S02-, -NH.CO.NH or -NH.CS.NH- and wherein R3 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly orthrough an oxygen or sulphur atom by an aromatic group, R4 is an aliphatic hydrocarbon group which is substituted through an oxygen atom by an aliphatic hydrocarbon group which is itself substituted by an aromatic group, R5 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, and R6 is hydrogen, an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, with the proviso that when R is a group -OR3, -NH.COR3 or -NH.CO.NHR3 then (FORMULA) excludes bicyclo(2, 2, 1)hept-2Z-enes and bicyclo(2, 2, 1)heptanes. The compounds are of value for use in pharmaceutical compositions particularly in the context of the inhibition of thromboxane activity.